Reta-Peptide Safety Rating & Test Results

As of 3 Sept 2026, Finnrick has published 250 independent lab tests of 14 peptides from Reta-Peptide: 187 passed, 62 failed, and 1 was not classifiable (incomplete data) under the default public standard, Purity Focus (HPLC purity at least 99.5%, fill within ±35% of the label claim). The latest test is dated 15 Aug 2026.

Finnrick ratings are recency-weighted pass percentages: newer tests count more, and vendors with thin test histories are pulled toward the peer baseline for that peptide, so a single result cannot look too certain. Samples are analyzed by independent partner laboratories and the results are published by Finnrick Analytics, which does not sell peptides and does not accept payment to alter ratings. Corrections to published data are recorded at finnrick.com/corrections.

Purchased from Reta-Peptide? Submit a sample to Finnrick for free independent lab testing — results are published publicly.

Are you Reta-Peptide? Finnrick offers professional testing services and a public launch program for peptide vendors.

Interactive charts, prices, and test history for this page load with JavaScript; the facts above are from Finnrick's published test database.

Reta-Peptide peptides tested by Finnrick, rated under the default public methodology.
PeptideFinnrick ratingLab testsLatest test
BPC-15750%1820 Jul 2026
Cagrilintide61%48 May 2026
CJC-129531%913 Jul 2026
GHK-Cu94%2720 Jul 2026
Ipamorelin82%1620 Jul 2026
Melanotan II62%515 Jun 2026
MOTS-c42%83 Aug 2026
NAD+29%43 Aug 2026
PT-14174%615 Aug 2026
Retatrutide84%8315 Aug 2026
SS-3184%412 Jun 2026
TB-50039%1220 Jul 2026
Tesamorelin47%1820 Jul 2026
Tirzepatide87%3613 Jul 2026